| Identification | Back Directory | [Name]
BREVISCAPIN | [CAS]
116122-36-2 | [Synonyms]
Lamps,
BREVISCAPIN
Scutellarin hydrate
Breviscapine,Erigeron Breviscapus
A natural extract containing apigenin 7-glucuronide and scutellarein 7-glucuronide
7-(β-D-Glucopyranuronosyloxy)-5,6-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one hydrate
5,6-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl--D-glucopyranosiduronic acid hydrate | [Molecular Formula]
C21H18O11.C21H18O12 | [MDL Number]
MFCD01741878 | [MOL File]
116122-36-2.mol | [Molecular Weight]
908.723 |
| Hazard Information | Back Directory | [Uses]
Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris[1][2]. | [Definition]
ChEBI: Scutellarin is the glycosyloxyflavone which is the 7-O-glucuronide of scutellarein. It has a role as an antineoplastic agent and a proteasome inhibitor. It is a glycosyloxyflavone, a glucosiduronic acid, a trihydroxyflavone and a monosaccharide derivative. It is functionally related to a scutellarein. It is a conjugate acid of a scutellarin(1-). | [References]
[1] Gao J, et al. Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review. Front Pharmacol. 2017 May 23;8:289. DOI:10.3389/fphar.2017.00289
[2] Wen L, et al. Breviscapine: A Review on its Phytochemistry, Pharmacokinetics and Therapeutic Effects. Am J Chin Med. 2021;49(6):1369-1397. DOI:10.1142/S0192415X21500646 |
|
|